New product penetration

565 views
488 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
565
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

New product penetration

  1. 1. New Product Penetration: Understanding & Accelerating New Product Uptakehttp://www.aarkstore.com/reports/New-Product-Penetration-Understanding-Accelerating-New-Product-Uptake-213044.html.Related Report Links: FirstImpact: FDA approval of Aubagio Consensus Outlook: Multiple Sclerosis Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules Pharmas Future Role in CME Therapy Trends: Rheumatoid Arthritis -- Consensus Outlook Module Therapy Trends: Rheumatoid Arthritis -- KOL Insight and Consensus Outlook Modules Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module Pharma Reputations: Managing Perceptions Pharma sales force shape, size and structure — where next? Sampling: A key business driver in a multi-channel environment Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma Effective Sales and Marketing Strategies for Orphan Drugs New Product Penetration: Understanding & Accelerating New Product Uptake Managing Investigator Initiated Research"Action is power"This advice is increasingly relevant for pharmaceutical companies when it comes to shaping the uptakecurve of new products in todays evolving markets.With rapidly changing market factors, new opinion leader groups and the importance of a productsclinical-economic benefits, finding effective ways to keep pace with these changes is critical. However,many pharma companies are not aware of this, and remain complacent about taking appropriate action.In New Product Penetration: Understanding & Accelerating New Product Uptake, FirstWord Dossierreviews the differences between complex pharmaceutical adoption curves versus simple textbook bellcurves. It identifies the latest key drivers and barriers to new product penetration. The report alsoexamines strategic tactics that big pharma are now using to improve their uptake curves.
  2. 2. Report OverviewNew Product Penetration: Understanding & Accelerating New Product Uptake summarises the key issuesaround this important subject. It includes exclusive feedback from in-depth interviews with experienceddirectors from leading pharmaceutical companies. The report discusses examples of pre and peri-launchtactics companies are using to improve product adoption. It also outlines key questions that you shouldconsider when looking to increase your new product uptake.Key Report FeaturesViews from global marketing directors of leading pharma companiesVarious tactics to help develop and deliver rapid product uptakeThe need for combined clinical and economic product benefitsThe importance of segmenting the market at a clinical, payer and patient levelStructural company changes to improve new product penetrationThe role of non-traditional KOL groups in securing market accessCoordination of cross-functional and geographic launch activitiesActions that big pharma companies are taking to improve product uptakeWho Would Benefit From This Report?This report will be of value to pharma directors and managers with responsibilities in the following areas:Market accessMarketingBusiness developmentBrand marketingSales managementPharmacoeconomicsClinical research developmentCorporate communicationsKey Opinion Leader liaisonPatient Advocacy liaisonMedical affairsKey Questions AnsweredWhy is the current environment for pharma product uptake so complex?Which mechanisms have companies adopted to accelerate new product uptake?Why issues to support rapid uptake remain unresolved?Which pre and peri-launch steps can effectively raise product uptake?How can Phase III trial design affect the uptake of new products?Which non-traditional KOL groups are now swaying rapid product uptake?How do the clinical vs. economic benefits of products affect growth curves?
  3. 3. When should you define a products overall value for your target markets?Key BenefitsUnderstand the multiple factors that affect new pharma product adoptionHear the tactics that industry leaders recommend to improve uptakeRecognise unresolved issues that still affect rapid product uptakePrevent and avert internal and external issues that delay market accessReview a checklist of key questions to ask when aiming to raise product uptakeIdentify ways to shape the target market uptake of your new productsKey quotes“Stalled or uneven product uptake is a classic sign of a lack of strategic segmentation,”– Bhupendra Patel, executive director, global marketing, Johnson & Johnson.“The way we launched in the past, with a good premarketing campaign and a major launch strategy,doesn’t works very well now because payers and governments have put up so many barriers in gettingaccess to the market,”– Stephen Lewington, senior director global marketing & medical affairs, Almirall.“The old, functional way of working created internal barriers to resource allocation. It prevented us fromlooking at the bigger picture. But the new market-based company structure has been a huge way for usto really accelerate market uptake,”– Uday Bose, European head of oncology, Eisai.“Market access strategy can make a lot of difference to speeding up adoption. Its no longer enough, ofcourse, for a product to be approved; somebody needs to pay for it,”– Ashwin Dandekar, senior vice president, Campbell Associates.“Key opinion leaders were once synonymous with clinical professionals but this is now a much broadercategory. The KOLs of the patient advocacy groups have become very influential, and they will bedirected by products to help their constituency,”– Ian Talmage, senior vice president, global marketing, Bayer.Expert ViewsIan Talmage, senior vice president, global marketing, BayerBhupendra Patel, executive director, global marketing, Johnson & JohnsonUday Bose, European head of oncology, EisaiStephen Lewington, senior director global marketing & medical affairs, AlmirallPhilippe Ghem, vice president, global brand lifecycle management, GrünenthalAshwin Dandekar, senior vice president, Campbell AllianceTable of Contents :
  4. 4. Executive summaryAbout this report: Methodology and the case study companiesIntroduction: Research underpinnings of product uptake> Product uptake: Standard model> Reflecting reality?> Homogeneity of market connectionsResearch findings> What market factors are driving the need for accelerated uptake of new products?> What practices have companies adopted to accelerate the uptake of new products?> Pre-launch activity> Peri-launch activity1. The importance of strategic marketing fundamentals2. The role of market access3. The importance of implementation rigour4. KOL engagement5. Evolving sales and marketing models> What barriers to rapid uptake remain unresolved?1. Product and proposition development capability2. Marketing capabilities3. Regulatory and compliance issues4. Internal barriersDiscussion and recommendations for practiceAcknowledgementsRelated Keywords : New Product, Penetration,Understanding, Accelerating, Uptake,Automotive, Automobile, Aerospace &Aviation, Banking, Consumer Goods, Construction, Chemicals, Defense, Diabetes, Disease, Drinks, Energy, Electronics,FinancialFor More details about above & other Reports plz contact :PranaliAarkstore.comContact: Marketing teamMob.No.918149852585Email: enquiry@aarkstore.com , discount@aarkstore.comURL: http://www.aarkstore.comhttp://in.linkedin.com/in/aarkstorehttp://www.facebook.com/aarkstore

×